Erlotinib Zydus 25/100/150 25 mg, 100 mg, 150 mg Tablets
PDF Leaflet Revision Date: 23 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of non-small cell lung cancer, bronchial adenocarcinoma, and pancreatic cancer.
Dosage (summary)
150 mg daily for NSCLC and bronchial adenocarcinoma; 100 mg daily with gemcitabine for pancreatic cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly population
- Paediatric population
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Warfarin
- Statins
Contraindications
- Severe hypersensitivity to erlotinib
Common side effects
- Rash
- Diarrhoea
- Fatigue
- Nausea
Counselling Points
- Take on an empty stomach
- Avoid smoking
- Monitor for severe skin reactions
Serious warnings
- Risk of ILD
- Gastrointestinal perforation
- Hepatic failure
Important Disclaimer
The Erlotinib Zydus 25/100/150 25 mg, 100 mg, 150 mg Tablets professional information leaflet below is the property of Zydus Healthcare Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
